Gene-correction therapy suffers setback but is still seen as promising

09/25/2013 | New York Times (tiered subscription model), The

Anecdotal reports from patients and data from small clinical trials have raised hopes that experimental drugs for Duchenne muscular dystrophy based on a new genetic technique called exon skipping could ultimately lead to a treatment. Drisapersen, an exon-skipping drug being developed by GlaxoSmithKline and Prosensa, failed to beat a placebo in preserving muscle function in boys with the disease in a large trial, but the idea of correcting faulty genes remains promising. "We are fully confident in the exon-skipping technology as a viable platform to develop a treatment for Duchenne," said Debra Miller, president of the advocacy group CureDuchenne.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ